Rxivist logo

Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure

By Fernando J Sánchez-Valdéz, Angel Padilla, Wei Wang, Dylan Orr, Rick Tarleton

Posted 19 Dec 2017
bioRxiv DOI: 10.1101/235762 (published DOI: 10.7554/elife.34039)

The ability of the Chagas disease agent Trypanosoma cruzi to resist extended in vivo exposure to highly effective trypanocidal compounds prompted us to explore the potential for dormancy and its contribution to failed drug treatments in this infection. We document the development of non-proliferating intracellular amastigotes in vivo and in vitro in the absence of drug treatment. Non-proliferative amastigotes ultimately converted to trypomastigotes and established infections in new host cells. Most significantly, dormant amastigotes were uniquely resistant to extended drug treatment in vivo and in vitro and could re-establish a flourishing infection after as many as 30 days of drug exposure. These results demonstrate a dormancy pathway in T. cruzi that accounts for the failure of highly cytotoxic compounds to completely resolve the infection. The ability of T. cruzi to establish dormancy throws into question current methods for identifying curative drugs but also suggests alternative therapeutic approaches.

Download data

  • Downloaded 413 times
  • Download rankings, all-time:
    • Site-wide: 38,976 out of 89,119
    • In microbiology: 2,693 out of 7,660
  • Year to date:
    • Site-wide: 62,559 out of 89,119
  • Since beginning of last month:
    • Site-wide: 42,804 out of 89,119

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)